Premium
BASELINE CLINICAL AND PET‐CT TUMOR BURDEN PARAMETERS DO NOT PREDICT OUTCOME OF RELAPSE/REFRACTORY AGGRESSIVE B CELL LYMPHOMA PATIENTS TREATED WITH ANTI‐CD19 CAR T‐CELLS
Author(s) -
Avigdor A.,
Davidson T.,
Shimoni A.,
Yerushalmi R.,
ShemTov N.,
Danylesko I.,
Itzhaki O.,
Toren A.,
Jacoby E.,
Besser M.,
Nagler A.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.188_2631
Subject(s) - medicine , fludarabine , lymphoma , refractory (planetary science) , cyclophosphamide , gastroenterology , nuclear medicine , surgery , oncology , chemotherapy , physics , astrobiology